Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!

Recruiting

A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis - IM027-040

Updated: 12 October, 2020   |   ClinicalTrials.gov

Print Friendly Summary

CONSIDERING THIS TRIAL?
Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 2

    Phase

  • Gender(s)

  • 21+

    Age Range

  • 75

    Location(s)

  • Recruiting

Treatment Options

Study Arms
ASSIGNED INTERVENTION
Experimental: IPF Dose 1 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Experimental: IPF Dose 2 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Placebo Comparator: IPF Placebo + Post Treatment Follow-up or OTE
Other: BMS-986278 Placebo
Experimental: PF-ILD Dose 1 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Experimental: PF-ILD Dose 2 + Post Treatment Follow-up or OTE
Drug: BMS-986278
Placebo Comparator: PF-ILD Placebo + Post Treatment Follow-up or OTE
Other: BMS-986278 Placebo

Key Eligibility Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: For the idiopathic pulmonary fibrosis (IPF) Cohort - Diagnosis of IPF within 7 years - Female and males ≥ 40 years of age For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort - Diagnosis of ILD within 7 years - Female and male ≥ 21 years of age. Exclusion Criteria: - Women of childbearing potential (WOCBP) - Active Smokers - Patients with current malignancy - History of allergy to BMS-986278 or related compounds Other protocol-defined inclusion/exclusion criteria apply

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Email Us

Have questions?
Email Us